#Sustainability #India #Renewable Energy #Mumbai #Piramal Pharma

Piramal Pharma's Commitment to Sustainability

Piramal Pharma Limited has made significant strides in its sustainability efforts as outlined in its recent Sustainability Report for 2025-26. As a global leader in the pharmaceuticals sector, the company is not just focused on business growth but is also deeply committed to environmental, social, and governance (ESG) principles. This report encapsulates how the company is integrating sustainability into every facet of its operations while remaining dedicated to serving the needs of its patients and communities.

Key Achievements

One of the notable highlights of the Sustainability Report is a remarkable 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared to the FY2022 baseline. This milestone marks a pivotal moment in the company's commitment to a Science Based Targets initiative (SBTi) approved decarbonisation roadmap. Furthermore, Piramal Pharma has increased its renewable energy consumption to 41% of its total energy usage across operations, contributing to a cleaner, more sustainable environmental impact.

To bolster its eco-friendly initiatives, the company has successfully recycled and reused 2.63 lakh kilolitres of freshwater and diverted 65% of its total waste for recycling. These efforts underscore Piramal Pharma's determination to operate responsibly and sustainably.

Quality and Operational Excellence

In addition to its environmental efforts, Piramal Pharma maintains an unwavering commitment to quality and operational excellence. The company successfully completed 38 regulatory inspections, including three from the USFDA, during which it received zero Official Action Indicated (OAI) observations. This achievement highlights the firm’s emphasis on the highest manufacturing standards across its global network.

Moreover, Piramal Pharma completed 209 customer audits, further reinforcing its adherence to quality and compliance standards. As part of its mission to enhance operational efficiency, the company announced a substantial $90 million investment to expand its advanced therapeutics capabilities at its Lexington and Riverview facilities.

Governance and People

On the governance side, Piramal Pharma has demonstrated commendable performance. The company reported zero data breaches and zero corruption cases during the reporting period, reflecting its commitment to ethical conduct and integrity. Employee training also reached impressive levels, with 100% completion rates for both ESG and Code of Conduct training.

Diversity and inclusion remain key focus areas for Piramal, evidenced by women holding 30% of board positions and constituting 20.1% of the global workforce. The company has made substantial progress in its responsible supply chain program, assessing 38% of critical suppliers against sustainability criteria.

Community Impact

In terms of community engagement, Piramal Pharma has invested ₹8.98 crore in Corporate Social Responsibility (CSR) initiatives during the fiscal year 2025-26. This investment has positively impacted nearly 1.8 million people across 112 Aspirational Districts through various healthcare and education programs. The company continues to enhance its relationships with stakeholders through community development, employee well-being initiatives, and responsible business practices.

Looking Ahead

Nandini Piramal, Chairperson of Piramal Pharma Limited, expressed that sustainability is seen not just as a requirement but as a driver for innovation, resilience, and growth. She noted that the progress highlighted in this year's report boosts their confidence in the strategic direction the company is taking. "We believe that innovation and sustainability can reinforce one another, enabling us to make better decisions today while creating greater value for tomorrow," said Nandini.

With a focused commitment to turning its sustainability ambitions into measurable actions, Piramal Pharma aspires to create a future-ready organization that not only improves health outcomes but also strengthens communities and delivers lasting value to all stakeholders. The company's sustainability framework revolves around four strategic pillars: Business Resilience, Quality Excellence, Responsible Operations, and Stakeholder Centricity, supported by over 50 time-bound sustainability targets across various critical areas.

In conclusion, Piramal Pharma is leading the way in sustainable practices in the pharmaceutical industry, showcasing that long-term viability can be achieved through responsible innovation and dedication to environmental stewardship. As the company moves forward, its integrated approach will be crucial for lasting impact and success in the decades to come.